Kalaris reports 53-fold lower TH103 plasma peak
Kalaris Therapeutics (NASDAQ:KLRS) reported expanded Phase 1a TH103 data from 20 patients, with plasma exposure up to 53-fold below leading anti-VEGF agents.

TV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Kalaris Therapeutics (NASDAQ:KLRS) reported expanded Phase 1a TH103 data from 20 patients, with plasma exposure up to 53-fold below leading anti-VEGF agents.
South Plains Financial (NASDAQ:SPFI) reported Q2 net income of $19 million and diluted EPS of $0.96, supported by its BOH acquisition.
Cadeler (NYSE:CDLR) took delivery of Wind Ace, its 11th installation vessel, expanding its capacity for offshore wind projects.
Bitcoin (CRYPTO:BTC) developers have introduced Dog mode as a response to the ongoing debate over spam and non-financial data on the Bitcoin network.
Wingara AG (ASX:WNR) appointed Christopher Hood as CEO on July 17 to lead its organic growth strategy.
Kraken launched USD-settled cryptocurrency options for institutional traders, allowing contracts to settle in US dollars instead of digital assets.
The US Senate has adopted a resolution opposing any pardon for former FTX chief Sam Bankman-Fried.
Hillgrove Resources (ASX:HGO) approved the development of the Emily Star underground mine extension.
Citadel Securities has invested US$400 million in Crypto.com, valuing the cryptocurrency exchange at US$20 billion.
Dimerix (ASX:DXB) secured an $10 million non-dilutive loan facility with SKIPTAN to fund its Phase 3 clinical trials.